Biotech Values

[turtlepower]

I kind of assumed the same thing. Universal coverage should provide more access to patients denied health care as is evidenced by this recent reuters article on breast cancer patients

http://www.reuters.com/article/idUSTRE63M4EM20100423

However I am surprised at how much big pharma is blaming HCR for their EPS shortcomings. If they did like the bill and expected added revenue from universal coverage, they probably would have mentioned that. Perhaps in the short term they are looking for an excuse for earnings shortcomings. One of the companies to complain, lilly as the article below points out, had other things going against them.

http://m.industry.bnet.com/pharma/10007795/7795/